184033-42-9Relevant articles and documents
Three-Dimensional Porous Architectures Based on MnII/III Three-Blade Paddle Wheel Metallacryptates
Marzaroli, Vittoria,Spigolon, Giulia,Lococciolo, Giuseppe,Quaretti, Martina,Salviati, Clarissa,Kampf, Jeff W.,Licini, Giulia,Marchiò, Luciano,Pecoraro, Vincent L.,Tegoni, Matteo
, p. 1954 - 1964 (2019/03/02)
Three metallacryptate supramolecular assemblies have been obtained using salicylhydroxamic acid derivatives (H3L). The three ligands differ in the residue at the para position with respect to the hydroxamic function (-H, -NH2, and -(
BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER
-
Paragraph 0713, (2015/02/18)
A compound of formula (I), useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.
Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors
Wang, Chao,Shi, Weiguo,Cai, Lifeng,Lu, Lu,Wang, Qian,Zhang, Tianhong,Li, Jinglai,Zhang, Zhenqing,Wang, Kun,Xu, Liang,Jiang, Xifeng,Jiang, Shibo,Liu, Keliang
, p. 2527 - 2539 (2013/05/21)
The small molecule fusion inhibitors N-(4-carboxy-3-hydroxyphenyl)-2,5- dimethylpyrrole (NB-2) and N-(3-carboxy-4-hydroxyphenyl)-2,5-dimethylpyrrole (A12) target a hydrophobic pocket of HIV-1 gp41 and have moderate anti-HIV-1 activity. In this
Syntheses, properties, and photoreactions of the hybrid molecules consisting of a CoII mononuclear complex and porphyrins
Kon, Hiroki,Nagata, Toshi
experimental part, p. 1781 - 1788 (2012/03/11)
New hybrid molecules consisting of mononuclear CoII complexes and porphyrin moieties were synthesized and their new photoreactions were examined. Three porphyrins with different meso-substituents (2,6- dimethoxyphenyl, 3,5-di-tert-butylphenyl,
URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA
-
Page/Page column 28, (2011/10/03)
The invention relates to a new class of compounds, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions that are effective as selective inhibitors of factor Xa, both in the isolated state and in a complex with other proteins. The compounds of the invention can be used for treating and preventing diseases, such as acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, thromboses caused by post-thrombolytic therapy or coronary angioplasty, acute ischemia mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, and other diseases in humans and other mammals associated with blood coagulation problems.
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats
Dhaneshwar, Suneela S.,Chail, Mukta,Patil, Mahavir,Naqvi, Salma,Vadnerkar, Gaurav
experimental part, p. 131 - 142 (2009/04/07)
Mutual amide prodrugs of 4-aminosalicylic acid with d-phenylalanine and l-tryptophan were synthesized for targeted drug delivery to the inflamed gut tissue in inflammatory bowel disease. Stability studies in aqueous buffers (pH 1.2 and 7.4) showed that the synthesized prodrugs were stable in both the buffers over a period of 10 h. In rat fecal matter the release of 4-aminosalicylic acid from the prodrugs was in the range of 86-91% over a period of 20 h, with half-lives ranging between 343 and 412 min following first order kinetics. Targeting potential of the carrier system and the ameliorating effect of the amide conjugates were evaluated in trinitrobenzenesulfonic acid-induced experimental colitis model in rats. The prodrugs were assessed for their probable damaging effects on pancreas and liver with the help of histopathological analysis and for their ulcerogenic potential by Rainsford's cold stress method. They were found to have improved safety profile than sulfasalazine, oral 4- and 5-aminosalicylic acid with similar pharmacological spectrum and advantages of sulfasalazine.
Derivaitves of 4-Or 5-Aminosalicylic Acid
-
Page/Page column 11; 21, (2008/12/08)
The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as infl
Derivatives of 4- or 5-aminosalicylic acid
-
Page/Page column 12-13; 21-26; 28-29, (2008/06/13)
The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.
THALIDOMIDE ANALOGS
-
Page/Page column 58, (2008/06/13)
Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
AMIDINOPHENYLPYRUVIC ACID DERIVATIVES
-
, (2008/06/13)
An amidinophenylpyruvic acid derivative of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an excellent antagonistic effect against activated blood coagulation factor VII.
